No causative genes or inheritance patterns applicable to adrenal gland neoplasm as a whole are certified in this packet. The category encompasses tumors arising through diverse and largely distinct molecular pathways. Within the MEN1 subtype specifically, GeneReviews documents that heterozygous pathogenic variants in the MEN1 gene are causative, following an autosomal dominant inheritance pattern. GeneReviews further documents age-related penetrance in MEN1: parathyroid primary hyperparathyroidism develops in 100% of MEN1 individuals by age 50, while anterior pituitary tumors occur in approximately 30–40% of affected individuals. These penetrance data apply exclusively to MEN1 and are not generalizable to other adrenal gland neoplasm subtypes. Subtypes such as pheochromocytoma-paraganglioma and adrenocortical carcinoma have distinct genetic associations that are not certified in the present packet fields.

Diagnostic criteria applicable to adrenal gland neoplasm as a class are not certified in this packet. Approaches to diagnosis are subtype-dependent, reflecting the heterogeneous origins of adrenal and endocrine tumors. Within the MEN1 subtype, GeneReviews describes a diagnostic framework centered on clinical recognition of parathyroid tumors manifesting as hypercalcemia, anterior pituitary tumors with associated hormonal syndromes, and pancreatico-enteric tumors. GeneReviews notes that MEN1 is considered in individuals with endocrine tumors, though non-endocrine tumors may present before endocrine manifestations. GeneReviews further states that no single clinical definition or criterion captures all individuals with MEN1 given the variability of tumor combinations observed. These diagnostic considerations apply specifically to MEN1 and are not generalizable to adrenal gland neoplasm as a class.

No FDA-approved treatments or foundational therapies applicable to adrenal gland neoplasm as a broad category are certified in this packet. Treatment approaches in clinical practice vary substantially by histologic subtype, hormonal secretory activity, malignant potential, tumor size, and disease stage. For the MEN1 subtype specifically, GeneReviews notes that clinical practice guidelines for MEN1 have been developed, with management organized around evaluations following initial diagnosis and ongoing tumor surveillance across affected organ systems. GeneReviews identifies a range of evaluations to establish the extent of disease in MEN1 following diagnosis. These management considerations are subtype-specific to MEN1 and are not generalizable to adrenal gland neoplasm as a class. No orphan drug designations are documented in this packet for adrenal gland neoplasm as a broad category.

Natural history data for adrenal gland neoplasm as a category is not certified in this packet. Prognosis differs substantially by tumor histology, anatomic origin, hormonal activity, malignant potential, and disease stage. For the MEN1 subtype, GeneReviews documents an age-related pattern of tumor development: parathyroid primary hyperparathyroidism occurs in 100% of MEN1 individuals by age 50, with anterior pituitary tumors developing in approximately 30–40% of affected individuals; among those anterior pituitary tumors, prolactinomas represent approximately 60%. GeneReviews notes that no single predictable clinical trajectory applies in MEN1 given the heterogeneous combination of tumor types observed across individuals. These observations are specific to MEN1 and do not represent the prognosis for adrenal gland neoplasm as a class.

Several clinical trials associated with adrenal gland neoplasm subtypes are documented in this packet. A prospective study of comprehensive molecular analysis of endocrine neoplasms (NCT01005654), sponsored by the National Cancer Institute, has been enrolling since October 2009. A study of the clinical and molecular characteristics of primary aldosteronism in Black individuals (NCT03374215), sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, is actively recruiting with a planned completion of December 2026. A Phase 2 interventional trial of PDS01ADC in combination with hepatic artery infusion pump therapy and systemic treatment, enrolling participants with metastatic adrenocortical carcinoma, metastatic colorectal cancer, or intrahepatic cholangiocarcinoma (NCT05286814), is being conducted by the National Cancer Institute, with enrollment since October 2022 and completion planned for December 2028. A study of the biodistribution of 68Ga-FAPi-46 in patients with solid tumors or hematologic malignancies (NCT07118176) is also listed.